journal article·2020-02

siRNA release kinetics from polymeric nanoparticles correlate with RNAi efficiency and inflammation therapy via oral delivery

Chunbai He, Haimei Yue, Lu Xu, Yifu Liu, Yudong Song, Cui Tang, Chunhua Yin

Acta Biomaterialia· Volume 103
Publisher page

Abstract

Despite many efforts in the rational design of nanoparticles (NPs) to overcome the biological barriers to small interfering RNA (siRNA) delivery for improving gene silencing efficiency, little is known about the correlations between siRNA release kinetics and RNA interference (RNAi) efficiency and inflammation therapy via oral delivery. On the basis of mannose-modified trimethyl chitosan-cysteine (MTC) polymers, seven types of MTC NPs containing tumor necrosis factor (TNF)-α siRNA were prepared through ionic gelation. The siRNA release kinetics from MTC NPs were finely tuned by adjusting the kinds and amounts of the crosslinkers involved. These MTC NPs exhibited no disparities in siRNA protection against enzymatic degradation in physiological fluids and cellular uptake in macrophages; however, they showed distinct in vitro siRNA release profiles and intracellular unpacking kinetics. MTC NPs with relatively rapid and sustained siRNA release were responsible for efficient, prompt, and prolonged RNAi, contributing to desired therapeutic efficacy in acute and chronic inflammatory murine models following oral delivery. However, MTC NPs insufficiently releasing siRNA could not elicit effective RNAi. Collectively, the present investigation might provide broad insights into the optimization of siRNA nanocarriers with respect to their release kinetics for improving RNAi efficacies aiming at different types of inflammatory diseases. STATEMENT OF SIGNIFICANCE: siRNA release kinetics in the cytoplasm and pathological characteristics of diseases themselves determine the therapeutic efficacy of siRNA delivery. Herein, by adjusting the kinds and amounts of the crosslinkers involved, we developed seven types of MTC NPs containing TNF-α siRNA with distinct siRNA release kinetics. MTC NPs with relatively rapid and sustained siRNA release were responsible for prompt and prolonged RNAi, respectively, contributing to desired therapeutic efficacy in acute and chronic inflammation following oral delivery. These results might provide broad insights into the optimization of siRNA nanocarriers in respect to their release kinetics for improving therapeutic outcomes toward different clinical requirements.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (39)

Show source-provided references
1. Knocking down disease: a progress report on siRNA therapeutics10.1038/nrg3978 ↗
2. Preclinical and clinical development of siRNA-based therapeutics10.1016/j.addr.2015.01.007 ↗
3. Recent progress in development of siRNA delivery vehicles for cancer therapy10.1016/j.addr.2016.06.011 ↗
4. A reduction and pH dual-Sensitive polymeric vector for long-circulating and tumor-targeted siRNA delivery10.1002/adma.201403877 ↗
5. Recent development of synthetic nonviral systems for sustained gene delivery10.1016/j.drudis.2017.04.001 ↗
6. Effective cytoplasmic release of siRNA from liposomal carriers by controlling the electrostatic interaction of siRNA with a charge-invertible peptide, in response to cytoplasmic pH10.1039/C5NR08365F ↗
7. pH-sensitive nanomicelles for high-efficiency siRNA delivery in vitro and in vivo: an insight into the design of polycations with robust cytosolic release10.1021/acs.nanolett.6b02915 ↗
8. Technologies for controlled, local delivery of siRNA10.1016/j.jconrel.2015.09.066 ↗
9. Conjugation chemistry through acetals toward a dextran-based delivery system for controlled release of siRNA10.1021/ja305552u ↗
10. Nanocarriers for vascular delivery of anti-inflammatory agents10.1146/annurev-pharmtox-011613-140002 ↗
11. Multifunctional nanocapsules for simultaneous encapsulation of hydrophilic and hydrophobic compounds and on-demand release10.1021/nn205023w ↗
12. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization10.1016/j.biomaterials.2010.12.029 ↗
13. Lipid nanoparticles with minimum burst release of TNF-α siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate10.1016/j.jconrel.2018.05.035 ↗
14. Tunable delivery of siRNA from a biodegradable scaffold to promote angiogenesis in vivo10.1002/adma.201303520 ↗
15. Prolonged gene silencing by combining siRNA nanogels and photochemical internalization, j10.1016/j.jconrel.2010.04.012 ↗
16. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo10.1002/anie.201203263 ↗
17. Effect of binding affinity for siRNA on the in vivo antitumor efficacy of polyplexes10.1016/j.biomaterials.2013.03.060 ↗
18. Multifunctional polymeric nanoparticles for oral delivery of TNF-α siRNA to macrophages10.1016/j.biomaterials.2013.01.033 ↗
19. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape10.1038/nbt.2612 ↗
20. Galactosamine-induced sensitization to the lethal effects of endotoxin10.1073/pnas.76.11.5939 ↗
21. Galactosylated trimethyl chitosan–cysteine nanoparticles loaded with MAP4K4 siRNA for targeting activated macrophages10.1016/j.biomaterials.2013.01.079 ↗
22. Orally delivered thioketal nanoparticles loaded with tnf-α-sirna target inflammation and inhibit gene expression in the intestines10.1038/nmat2859 ↗
23. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency10.1016/j.jconrel.2013.12.026 ↗
24. Stability, intracellular delivery, and release of siRNA from chitosan nanoparticles using different cross-linkers
25. siRNA delivery strategies: a comprehensive review of recent developments10.3390/nano7040077 ↗
26. Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models10.1016/j.drudis.2011.01.003 ↗
27. Formulation of chitosan-TPP-pDNA nanocapsules for gene therapy applications10.1088/0957-4484/22/1/015101 ↗
28. Hyaluronic acid/chitosan-g-Poly(ethylene glycol) nanoparticles for gene therapy: an application for pDNA and siRNA delivery10.1007/s11095-010-0263-y ↗
29. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers: I. manipulation of drug release using eudragit®; L100-55 and eudragit®; S100 combinations10.1016/S0168-3659(98)00151-5 ↗
30. Self-assembled nanoparticles based on linoleic-acid modified chitosan: stability and adsorption of trypsin10.1016/j.carbpol.2005.08.010 ↗
31. Comparative structural and functional studies of nanoparticle formulations for DNA and siRNA delivery10.1016/j.nano.2010.07.005 ↗
32. Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery10.1016/j.biomaterials.2016.02.031 ↗
33. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging10.1093/nar/gkj439 ↗
34. Rational design of cationic lipids for siRNA delivery10.1038/nbt.1602 ↗
35. Predictive modeling of non-viral gene transfer10.1002/bit.22604 ↗
36. In vivo sustained release of siRNA from solid lipid nanoparticles10.1021/nn203745n ↗
37. In vivo therapeutic efficacy of TNFα silencing by folate-PEG-chitosan-DEAE/siRNA nanoparticles in arthritic mice10.2147/IJN.S146942 ↗
38. Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease10.1016/j.jconrel.2010.10.002 ↗
39. Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis10.2217/nnm-2017-0196 ↗